Changing Landscape of Diagnosis and Treatment of Multiple Myeloma – Live

Description

Program Description

---

Click to Go to the Event Registration

This webinar provides an update on the diagnostic criteria based on the cytogenetic and genomics of MM, benefits and risks of frontline therapy, consolidation, and maintenance therapy options, sequencing therapies, CAR-modified T-cell therapy, bispecific antibody constructs, and antibody-drug conjugate (ADC) based treatment for patients with MM.

Agenda

---

• Update on multiple myeloma (MM) disease definitions and diagnostic criteria based on IMWG guidelines – Gareth Morgan, MD
• Updates in frontline therapy for MM – Shaji Kumar, MD
• An approach to consolidation and maintenance therapy for MM – Cesar Rodriguez, MD
• Selecting and sequencing therapies in relapsed MM – Saad Z. Usmani, MD, MBA, FACP
• BCMA as a therapeutic target and advantages of CAR-modified T-cell therapy for MM – Nikhil Munshi, MD
• Therapeutic potential of bispecific antibody constructs, including BiTE (bispecific T-cell engager) and antibody-drug conjugate (ADC), in the treatment of patients with MM – Al-Ola Abdallah, MD

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses involved in multiple myeloma (MM) patient care.

Commercial Supporter

---

Supported by an educational grant from Sanofi.